NCT07139548View on ClinicalTrials.gov

A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

600

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

December 31, 2026

Conditions

T2DM

Interventions

DRUG

RAY1225

Administered SC

DRUG

Semaglutide

Administered SC

Trial Locations (1)

Unknown

Peking University People's Hospital, Beijing

All Listed Sponsors

lead

Guangdong Raynovent Biotech Co., Ltd

INDUSTRY